MedTrace Logo

Safety and Immunogenicity of a Split-Virion Pandemic Influenza A (H5N1) Vaccine in Adolescents

NCT00900588 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2009-08-12

No results posted yet for this study

Summary

A single center, stratified, randomized and double-blind phase II clinical trial was conducted in adolescents to evaluate the safety and immunogenicity of a split-virion pandemic influenza A vaccine (H5N1).

Conditions

Interventions

BIOLOGICAL

split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)

Sponsors & Collaborators

  • Centers for Disease Control and Prevention, China

    collaborator OTHER_GOV

  • Sinovac Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00900588 on ClinicalTrials.gov